RespireRx Pharmaceuticals Inc. to Present at the 2017 Marcum
MicroCap Conference
CEO to review: dronabinol, a Phase 3-ready medicine for the
treatment of obstructive sleep apnea; and ampakines, Phase 2 drug
candidates for multiple disrupted respiratory indications
GLEN ROCK, NJ-(Marketwired - Jun 14, 2017) - RespireRx
Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"),
a leader in the development of medicines for the treatment of
respiratory disorders for which there are no approved
pharmaceuticals, particularly sleep apneas and respiratory
depression resulting from pain management medicines and
disabilities such as spinal cord injury, announces that the
Company's President, Chief Executive Officer and Vice Chairman of
the Board of Directors, James S. Manuso, Ph.D., will present at the
2017 Marcum MicroCap Conference on Friday, June 16, 2017 at 10:00
AM Eastern Standard Time. The Conference is organized by Marcum
LLP, an independent public accounting and advisory services firm.
Presentations will be held at the Grand Hyatt Hotel in New York
from June 15 - 16, 2017.
Dr. Manuso will discuss results from the successfully completed
PACE Phase 2B trial, conducted by Dr. David Carley and colleagues
at the University of Illinois at Chicago and Northwestern
University, in which dronabinol (oral) was tested for the treatment
of obstructive sleep apnea ("OSA"). In addition, Dr. Manuso will
discuss results from a successfully completed Phase 2A trial, in
which acutely administered CX-1739 (oral) reduced opioid-induced
respiratory depression in a clinical model of chronic opioid
consumption. Dr. Manuso will also provide a summary of near term
plans and goals, background information and descriptions of other
product pipeline candidates.
Dr. Manuso's presentation will be available by live webcast
streaming online and archived for 90 days. To access the webcast,
go to http://wsw.com/webcast/marcum5/rspi or visit the RespireRx
website at www.respirerx.com, click on the same link on the home
page, or, click on the Investors tab and follow the links to this
press release and click the webcast link.
A copy of the slide presentation to be presented at the
conference will be submitted to the Securities and Exchange
Commission in a Current Report on Form 8-K prior to the
presentation and will also be available in the investors section of
the RespireRx website.
Comments by the Company's President and Chief Executive Officer
Dr. James S. Manuso, commented, "We are pleased to be represented
at this very important microcap conference, especially after having
the dronabinol and CX1739 opportunities presented at the Sleep 2017
meeting last week in Boston, MA, where our efforts were well
received by the medical and research community. Obstructive sleep
apnea and opioid induced respiratory depression, our most mature
programs, as well as all of our other programs, all addressing
neurologically controlled disordered breathing, are aimed at
critically important poorly met or unmet medical needs. I look
forward to reporting to you on our progress in the months
ahead."
About RespireRx Pharmaceuticals Inc. RespireRx Pharmaceuticals
Inc. is a leader in the development of medicines for respiratory
disorders, with a focus on sleep apneas and drug-induced
respiratory depression. The Company owns patents and patent
applications, and holds exclusive licenses, for certain families of
chemical compounds that claim the chemical structures and their use
in the treatment of these and other disorders. Pending additional
funding, during 2017, the Company plans to: 1) meet with the FDA to
discuss its Phase 3 clinical trial program to test the safety and
efficacy of dronabinol (oral) for the treatment of OSA; 2) file an
IND and initiate a Phase 2 clinical trial investigating the ability
of CX717 to improve breathing in patients with spinal cord injury;
and 3) file an IND and initiate a Phase 2 clinical trial
investigating the ability of CX1739 to reduce central sleep apnea
in patients taking chronic opioids.
RespireRx's pharmaceutical candidates in development are derived
from two platforms, as described below.
The first platform is the class of compounds known as
cannabinoids, including dronabinol. Under a license agreement with
the University of Illinois, the Company has rights to patents
claiming the use of cannabinoids for the treatment of sleep-related
breathing disorders. As reported in a press release and on Form 8-K
on December 23, 2016, Dr. David Carley and colleagues at the
University of Illinois at Chicago and Northwestern University
successfully completed the PACE (Pharmacotherapy of Apnea by
Cannabimimetic Enhancement) trial, a potentially pivotal, six week,
double-blind, placebo-controlled Phase 2B study of dronabinol for
the treatment of OSA. Dronabinol significantly improved the primary
outcome measures of Apnea Hypopnea Index ("AHI"), daytime
sleepiness as measured by the Epworth Sleepiness Scale ("ESS") and
overall patient satisfaction as measured by the Treatment
Satisfaction Questionnaire for Medications ("TSQM"). This study was
fully funded by the National Heart, Lung and Blood Institute of the
National Institutes of Health. The Company did not manage or fund
this clinical trial.
In an earlier placebo-controlled, dose-ascending Phase 2A
clinical study conducted by the Company, dronabinol produced a
statistically significant reduction in the AHI, the primary
therapeutic end-point, and was observed to be safe and
well-tolerated in a group of patients with OSA.
The second platform of medicines being developed by RespireRx is
a class of proprietary compounds known as ampakines that act to
enhance the actions of the excitatory neurotransmitter glutamate at
AMPA glutamate receptor sites in the brain. Several ampakines in
both oral and injectable form are being developed by the Company
for the treatment of a variety of breathing disorders. In a
recently completed Phase 2A clinical trial, acute administration of
CX-1739 (oral) reduced the respiratory depression produced by
remifentanil, a potent opioid, in a clinical model of chronic
opioid consumption, without altering its analgesic effects.
Furthermore, ampakines have have been demonstrated to improve
breathing in animal models of disorders such as spinal cord injury,
Pompé Disease, and perinatal respiratory distress. The Company's
compounds belong to a new class of ampakines that do not display
the undesirable side effects previously reported for earlier
generations of ampakines.
Additional information about the Company and the matters
discussed herein can be obtained on the Company's web-site at
www.RespireRx.com or in the Company's filings with the U.S.
Securities and Exchange Commission on EDGAR at www.sec.gov.
Special Note Regarding Forward-Looking Statements:
Certain statements included or incorporated by reference in this
news release, including information as to the future financial or
operating performance of the Company and its drug development
programs, constitute forward-looking statements. The words
"believe," "expect," "anticipate," "contemplate," "target," "plan,"
"intend," "continue," "budget," "estimate," "may," "schedule" and
similar expressions identify forward-looking statements.
Forward-looking statements include, among other things, statements
regarding future plans, targets, estimates and assumptions.
Forward-looking statements are necessarily based upon a number of
estimates and assumptions that, while considered reasonable by the
Company, are inherently subject to significant business, economic
and competitive uncertainties and contingencies. Many factors could
cause the Company's actual results to differ materially from those
expressed or implied in any forward-looking statements made by, or
on behalf of, the Company. Due to these various risks and
uncertainties, actual events may differ materially from current
expectations. Investors are cautioned that forward-looking
statements are not guarantees of future performance and,
accordingly, investors are cautioned not to put undue reliance on
forward-looking statements due to the inherent uncertainty therein.
Forward-looking statements are made as of the date of this news
release and the Company disclaims any intent or obligation to
update publicly such forward-looking statements, whether as a
result of new information, future events or results or
otherwise.
Company Contact: Jeff Margolis Vice-President, Treasurer and
Secretary Telephone: (917) 834-7206 E-mail:
jmargolis@respirerx.com
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Aug 2024 to Sep 2024
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Sep 2023 to Sep 2024